Dasatinib suppresses cell adhesion, migration, and invasion of prostate cancer cells by blocking the kinase activities of the SFKs, Lyn, and Src, in human prostate cancer cells at low concentrations.
focal adhesion kinase and crk-associated substrate (p130 (cas) ) signaling downstream of sfks are also inhibited (nam et al. , 2005).